同步放化疗治疗局部晚期非小细胞肺癌的临床疗效及安全性  

Clinical efficacy and safety of concurrent chemo-radiotherapy in locally advanced non-small cell lung cancer

作　　者：冀晓辉[1] 翁克贵[1] 黄露迷[1] 

机构地区：[1]重庆市肿瘤医院肿瘤内科,重庆400030

出　　处：《中国肿瘤临床与康复》2016年第1期56-58,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨同步放化疗治疗局部晚期非小细胞肺癌(NSCLC)的临床疗效及安全性。方法选取2011年1月至2014年1月间收治的90例局部晚期NSCLC患者,根据随机数字表法分为观察组和对照组,每组45例。观察组患者接受同步放化疗,对照组患者接受序贯放化疗。比较两组治疗的近期临床疗效、1年生存率、不良反应以及生活质量评分。结果与对照组相比,观察组患者有效率、1年生存率均明显升高,差异有统计学意义(P<0.05);不良反应发生率略有升高,但差异无统计学意义(P>0.05);生活质量各维度评分及总分均明显提高,差异有统计学意义(P<0.05)。结论同步放化疗能够提高局部晚期NSCLC患者的临床疗效及生活质量,具有较高的安全性。Objective To explore the clinical efficacy and safety of concurrent chemo-radiotherapy in locally advanced non-small cell lung cancer（ NSCLC）. Methods From January 2011 to January 2014 in Chongqing Cancer Hospital,90 locally advanced NSCLC patients were enrolled in the study and randomized into the observation group and the control group,45 cases in each group. The patients in the observation group accepted concurrent chemo-radiotherapy and those in the control group accepted sequential chemo-radiotherapy. The recent clinical efficacy,1-yr survival rate,adverse reactions and life of quality between the two groups were compared. Results Compared with the control group,the effective rate and 1-yr survival rate were significantly increased in the observation group,with significant difference（ P〈0. 05）;the incidences of adverse reactions was slightly increased in the observation group,but without significant difference（ P〉0. 05）; the each dimension scores of life quality and total score were obviously improved in the observation group,with significant difference（ P〈0. 05）. Conclusion Concurrent chemo-radiotherapy can significantly improve clinical efficacy and life quality for patients with locally advanced NSCLC,with higher safety.

关 键 词：肺肿瘤 同步放化疗 治疗结果 安全性 

分 类 号：R734.2[医药卫生—肿瘤]